Shares of 10x Genomics TXG remained unaffected after the company reported Q1 results.
Quarterly Results
Earnings per share rose 186.96% over the past year to $0.66, which beat the estimate of $0.50.
Revenue of $231,200,000 higher by 34.42% from the same period last year, which missed the estimate of $232,000,000.
Guidance
10x Genomics hasn't issued any earnings guidance for the time being.
10x Genomics hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: May 13, 2021
Time: 09:00 AM
ET Webcast URL: https://services.choruscall.com/mediaframe/webcast.html?webcastid=mn0CsRHj
Recent Stock Performance
Company's 52-week high was at $203.25
52-week low: $72.04
Price action over last quarter: down 7.08%
Company Overview
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.